Novel engineered TRAIL‐based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance
Rozga, Piotr, Kloska, Damian, Pawlak, Sebastian, Teska‐Kaminska, Malgorzata, Galazka, Marlena, Bukato, Katarzyna, Pieczykolan, Anna, Jaworski, Albert, Molga‐Kaczmarska, Anna, Kopacz, Aleksandra, Badyra, Bogna, Kachamakova‐Trojanowska, Neli, Zolnierkiewicz, Olga, Targosz‐Korecka, Marta, Poleszak, Katarzyna, Szymanik, Michal, Zerek, Bartlomiej, Pieczykolan, Jerzy, Jozkowicz, Alicja, Grochot‐Przeczek, Anna
Published in International journal of cancer (15.08.2020)
Published in International journal of cancer (15.08.2020)
Get full text
Journal Article
CPL207280, a Novel G Protein–Coupled Receptor 40/Free Fatty Acid Receptor 1–Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals
Bazydlo-Guzenda, Katarzyna, Buda, Pawel, Matloka, Mikolaj, Mach, Mateusz, Stelmach, Filip, Dzida, Radoslaw, Smuga, Damian, Hucz-Kalitowska, Joanna, Teska-Kaminska, Malgorzata, Vialichka, Varvara, Dubiel, Krzysztof, Kaminska, Bozena, Wieczorek, Maciej, Pieczykolan, Jerzy
Published in Molecular pharmacology (01.10.2021)
Published in Molecular pharmacology (01.10.2021)
Get full text
Journal Article
ANTICANCER FUSION PROTEIN
PIECZYKOLAN ANNA MARIA, ROZGA PIOTR, JAWORSKI ALBERT ROBERT, ZEREK BARTLOMIEJ MACIEJ, PIECZYKOLAN JERZY SZCZEPAN, TESKA KAMINSKA MALGORZATA IZABELA, SZYMANIK MICHAL, PAWLAK SEBASTIAN
Year of Publication 06.08.2014
Get full text
Year of Publication 06.08.2014
Patent
2333-PUB: CPL207-280, a Potent and Safe GPR40 Agonist for the treatment of Type 2 Diabetes
BAZYDLO-GUZENDA, KATARZYNA, BUDA, PAWEL, KOZLOWSKA, IZABELA, MACH, MATEUSZ, TESKA-KAMINSKA, MALGORZATA, STELMACH, FILIP, WASINSKA-KALWA, MALGORZATA, GALAZKA, KINGA, DUBIEL, KRZYSZTOF K., PIECZYKOLAN, JERZY S., WIECZOREK, MACIEJ
Published in Diabetes (New York, N.Y.) (01.06.2019)
Published in Diabetes (New York, N.Y.) (01.06.2019)
Get full text
Journal Article
Abstract 4471: AD-O64.4 - a novel bioconjugate for tumor-targeted drug delivery
Strozek, Wojciech, Pieczykolan, Anna, Zerek, Bartlomiej, Szymanik, Michal, Jaworski, Albert, Galazka, Marlena, Bukato, Katarzyna, Rozga, Piotr, Pawlak, Sebastian, Poleszak, Katarzyna, Teska-Kaminska, Malgorzata, Pieczykolan, Jerzy
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Get full text
Journal Article
Abstract 3796: Biochemical and biophysical characterization of AD-O51.4 a novel anticancer biological therapeutic agent with dual mechanism of action
Pawlak, Sebastian D., Pieczykolan, Jerzy S., Zerek, Bartlomiej, Poleszak, Katarzyna, Teska-Kaminska, Malgorzata, Galaska, Marlena, Szymanik, Michal, Jaworski, Albert, Pieczykolan, Anna, Bukato, Katarzyna, Strozek, Wojciech, Rozga, Piotr K.
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Get full text
Journal Article
Abstract 2600: Preclinical evaluation of the novel fusion molecule with high dual antiangiogenic and anticancer potential
Pieczykolan, Jerzy S., Pieczykolan, Anna, Rozga, Piotr, Pawlak, Sebastian, Zerek, Bartlomiej, Teska - Kaminska, Malgorzata, Michal, Szymanik, Jaworski, Albert, Erlemann, Karl R., Capala, Jacek
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Get full text
Journal Article
Abstract 2773: AD-O56.9: A fusion of TRAIL/Apo2L with a membrane disrupting peptide as a novel anticancer therapeutic
Zerek, Bartlomiej Maciej, Szymanik, Michal, Rozga, Piotr Kamil, Pieczykolan, Anna, Galazka, Marlena, Bukato, Katarzyna, Jaworski, Albert, Poleszak, Katarzyna, Pawlak, Sebastian Dominik, Teska-Kaminska, Malgorzata, Strozek, Wojciech, Pieczykolan, Jerzy Szczepan
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Get full text
Journal Article
Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study
Matłoka, Mikołaj, Janowska, Sylwia, Gajos-Draus, Anna, Ziółkowski, Hubert, Janicka, Monika, Perko, Przemysław, Kamil, Kisło, Pankiewicz, Piotr, Moszczyński-Pętkowski, Rafał, Mach, Mateusz, Dera, Paulina, Abramski, Krzysztof, Teska-Kamińska, Małgorzata, Tratkiewicz, Ewa, Wieczorek, Maciej, Pieczykolan, Jerzy
Published in Pulmonary pharmacology & therapeutics (01.06.2022)
Published in Pulmonary pharmacology & therapeutics (01.06.2022)
Get full text
Journal Article
Abstract 5488: Fusion protein capable to initiate two apoptotic pathways in cancer cells resistant to classical PARA's
Pieczykolan, Jerzy S., Pawlak, Sebastian D., Zerek, Bartlomiej M., Rozga, Piotr K., Pieczykolan, Anna, Szymanik, Michal, Jaworski, Albert, Galazka, Marlena, Strozek, Wojciech, Wiciejowska, Katarzyna, Teska-Kaminska, Malgorzata, Kutner, Lukasz
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Get full text
Journal Article
Abstract 5073: Novel fusion molecule with high dual antiangiogenic and anticancer potential
Pieczykolan, Jerzy S., Rozga, Piotr, Pieczykolan, Anna, Zerek, Bartlomiej, Pawlak, Sebastian D., Szymanik, Michal, Jaworski, Albert, Galazka, Marlena, Wiciejowska, Katarzyna, Strozek, Wojciech, Teska - Kaminska, Malgorzata, Kutner, Lukasz, Grochot - Przeczek, Anna, Kahmakowa - Trojanowska, Neli
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Get full text
Journal Article
AD-O53.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L
Pieczykolan, Jerzy S., Kubiński, Konrad, Masłyk, Maciej, Pawlak, Sebastian D., Pieczykolan, Anna, Rózga, Piotr K., Szymanik, Michał, Gałązka, Marlena, Teska-Kamińska, Małgorzata, Żerek, Bartłomiej, Bukato, Katarzyna, Poleszak, Katarzyna, Jaworski, Albert, Strożek, Wojciech, Świder, Robert, Zieliński, Rafał
Published in Investigational new drugs (01.12.2014)
Published in Investigational new drugs (01.12.2014)
Get full text
Journal Article
AD-053.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L
PIECZYKOLAN, Jerzy S, KUBINSKI, Konrad, BUKATO, Katarzyna, POLESZAK, Katarzyna, JAWORSKI, Albert, STROZEK, Wojciech, SWIDER, Robert, ZIELINSKI, Rafał, MASLYK, Maciej, PAWLAK, Sebastian D, PIECZYKOLAN, Anna, ROZGA, Piotr K, SZYMANIK, Michał, GALAZKA, Marlena, TESKA-KAMINSKA, Małgorzata, ZEREK, Bartłomiej
Published in Investigational new drugs (2014)
Get full text
Published in Investigational new drugs (2014)
Journal Article
ANTICANCER FUSION PROTEIN
PIECZYKOLAN ANNA MARIA, JAWORSKI ALBERT ROBERT, ZEREK BARTLOMIEJ MACIEJ, PIECZYKOLAN JERZY SZCZEPAN, TESKA KAMINSKA MALGORZATA IZABELA, SZYMANIK MICHAL, RÓZGA PIOTR, PAWLAK SEBASTIAN
Year of Publication 11.09.2015
Get full text
Year of Publication 11.09.2015
Patent
ANTICANCER FUSION PROTEIN
TESKA-KAMINSKA MALGORZATA IZABELA, PIECZYKOLAN ANNA MARIA, JAWORSKI ALBERT ROBERT, ZEREK BARTLOMIEJ MACIEJ, PIECZYKOLAN JERZY SZCZEPAN, SZYMANIK MICHAL, RÓZGA PIOTR, PAWLAK SEBASTIAN
Year of Publication 12.02.2015
Get full text
Year of Publication 12.02.2015
Patent